Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Røge, Rikke M ; Bagger, Jonatan I ; Alskär, Oskar ; Kristensen, Niels R ; Klim, Søren ; Holst, Jens J ; Ingwersen, Steen Hvass ; Karlsson, Mats O ; Knop, Filip K ; Vilsbøll, Tina ; Kjellsson, Maria C. / Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose. In: Basic & clinical pharmacology & toxicology. 2017 ; Vol. 121, No. 4. pp. 290-297.

Bibtex

@article{fb836acfbd5b407dad443a03e79ecd2f,
title = "Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose",
abstract = "The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), play an important role in glucose homeostasis by potentiating glucose-induced insulin secretion. Furthermore, GLP-1 has been reported to play a role in glucose homeostasis by inhibiting glucagon secretion and delaying gastric emptying. As the insulinotropic effect of GLP-1 is preserved in patients with type 2 diabetes (T2D), therapies based on GLP-1 have been developed in recent years, and these have proven to be efficient in the treatment of T2D. The endogenous secretion of both GIP and GLP-1 is stimulated by glucose in the small intestine, and the release is dependent on the amount. In this work, we developed a semi-mechanistic model describing the release of GIP and GLP-1 following ingestion of various glucose doses in healthy volunteers and patients with T2D. In the model, the release of both hormones is stimulated by glucose in the proximal small intestine, and no differences in the secretion dynamics between healthy individuals and patients with T2D were identified after taking differences in glucose profiles into account. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article",
author = "R{\o}ge, {Rikke M} and Bagger, {Jonatan I} and Oskar Alsk{\"a}r and Kristensen, {Niels R} and S{\o}ren Klim and Holst, {Jens J} and Ingwersen, {Steen Hvass} and Karlsson, {Mats O} and Knop, {Filip K} and Tina Vilsb{\o}ll and Kjellsson, {Maria C}",
note = "This article is protected by copyright. All rights reserved.",
year = "2017",
month = "10",
doi = "10.1111/bcpt.12792",
language = "English",
volume = "121",
pages = "290--297",
journal = "Basic & Clinical Pharmacology & Toxicology Online",
issn = "1742-7843",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose

AU - Røge, Rikke M

AU - Bagger, Jonatan I

AU - Alskär, Oskar

AU - Kristensen, Niels R

AU - Klim, Søren

AU - Holst, Jens J

AU - Ingwersen, Steen Hvass

AU - Karlsson, Mats O

AU - Knop, Filip K

AU - Vilsbøll, Tina

AU - Kjellsson, Maria C

N1 - This article is protected by copyright. All rights reserved.

PY - 2017/10

Y1 - 2017/10

N2 - The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), play an important role in glucose homeostasis by potentiating glucose-induced insulin secretion. Furthermore, GLP-1 has been reported to play a role in glucose homeostasis by inhibiting glucagon secretion and delaying gastric emptying. As the insulinotropic effect of GLP-1 is preserved in patients with type 2 diabetes (T2D), therapies based on GLP-1 have been developed in recent years, and these have proven to be efficient in the treatment of T2D. The endogenous secretion of both GIP and GLP-1 is stimulated by glucose in the small intestine, and the release is dependent on the amount. In this work, we developed a semi-mechanistic model describing the release of GIP and GLP-1 following ingestion of various glucose doses in healthy volunteers and patients with T2D. In the model, the release of both hormones is stimulated by glucose in the proximal small intestine, and no differences in the secretion dynamics between healthy individuals and patients with T2D were identified after taking differences in glucose profiles into account. This article is protected by copyright. All rights reserved.

AB - The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), play an important role in glucose homeostasis by potentiating glucose-induced insulin secretion. Furthermore, GLP-1 has been reported to play a role in glucose homeostasis by inhibiting glucagon secretion and delaying gastric emptying. As the insulinotropic effect of GLP-1 is preserved in patients with type 2 diabetes (T2D), therapies based on GLP-1 have been developed in recent years, and these have proven to be efficient in the treatment of T2D. The endogenous secretion of both GIP and GLP-1 is stimulated by glucose in the small intestine, and the release is dependent on the amount. In this work, we developed a semi-mechanistic model describing the release of GIP and GLP-1 following ingestion of various glucose doses in healthy volunteers and patients with T2D. In the model, the release of both hormones is stimulated by glucose in the proximal small intestine, and no differences in the secretion dynamics between healthy individuals and patients with T2D were identified after taking differences in glucose profiles into account. This article is protected by copyright. All rights reserved.

KW - Journal Article

U2 - 10.1111/bcpt.12792

DO - 10.1111/bcpt.12792

M3 - Journal article

VL - 121

SP - 290

EP - 297

JO - Basic & Clinical Pharmacology & Toxicology Online

JF - Basic & Clinical Pharmacology & Toxicology Online

SN - 1742-7843

IS - 4

ER -

ID: 51414110